Whole-body MRI in Gaucher disease; monitoring disease activity, early detection of complications and treatment decision-making

Whole-body MRI in Gaucher disease; monitoring disease activity, early detection of complications and treatment decision-making - IMAGO study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44801

Enrollment

Registered

2013-12-13

Start date

2014-05-19

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gaucher disease glucosylceramidosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age >18 years Ability to provide informed consent Patients: confirmed diagnosis Gaucher disease Controls: resemblance in age and sex to matched patient

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Secondary

Measure	Time frame
- Comparison of ironmeasurements with standard care monitoring, that is liver- and spleenvolumes, QCSI and BMB-scores. - Relation ironmeasurements with biochemical GD markers - The value of extending the QCSI measurements, including tibia and fibula - Reproducibility of the whole-body MRI protocol	—

Primary

Measure	Time frame
The main study parameter is the difference in the measured ironlevels (expressed as R2*, a MRI based value correlating with ironconcentration (µmol/ g)) between Gaucherpatients and healthy controls.	—

Countries

Netherlands

Outcome results